Leland Gershell
Stock Analyst at Oppenheimer
(4.48)
# 324
Out of 4,711 analysts
123
Total ratings
46.55%
Success rate
31.02%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $56.12 | +35.42% | 1 | Dec 20, 2024 | |
| ARGX argenx SE | Reiterates: Outperform | $646 → $675 | $623.82 | +8.20% | 5 | Nov 21, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $190 → $180 | $136.38 | +31.98% | 10 | Nov 15, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $48 → $52 | $23.80 | +118.49% | 2 | Nov 11, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $135 → $147 | $114.64 | +28.23% | 2 | Nov 8, 2024 | |
| VERU Veru Inc. | Reiterates: Outperform | $5 | $0.65 | +670.30% | 8 | Nov 5, 2024 | |
| EPIX ESSA Pharma | Downgrades: Perform | n/a | $1.60 | - | 2 | Nov 4, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $65 → $73 | $45.18 | +61.58% | 8 | Oct 28, 2024 | |
| URGN UroGen Pharma | Reiterates: Outperform | $40 | $10.64 | +275.94% | 9 | Oct 16, 2024 | |
| IMVT Immunovant | Maintains: Outperform | $47 → $53 | $25.86 | +104.95% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $26.49 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $43 | $13.07 | +229.00% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $5.83 | +414.58% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.65 | +158.06% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $1.21 | +1,966.12% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $19.03 | +47.14% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $5.39 | +363.82% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $53.60 | +36.19% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $2.76 | +624.64% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $21.27 | +36.34% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $8.91 | +292.82% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $1.01 | +890.10% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.49 | +43.27% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $4.05 | +122.22% | 2 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.65 | +1,112.12% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $245.44 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.80 | +622.22% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $0.61 | +554.34% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $65.66 | - | 2 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.40 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7,200 | $0.32 | +2,248,494.63% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $22.09 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.65 | +1,786.79% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $0.46 | - | 5 | Mar 31, 2020 |
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $56.12
Upside: +35.42%
argenx SE
Nov 21, 2024
Reiterates: Outperform
Price Target: $646 → $675
Current: $623.82
Upside: +8.20%
Ascendis Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $190 → $180
Current: $136.38
Upside: +31.98%
Dianthus Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $23.80
Upside: +118.49%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $114.64
Upside: +28.23%
Veru Inc.
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.65
Upside: +670.30%
ESSA Pharma
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.60
Upside: -
Soleno Therapeutics
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $45.18
Upside: +61.58%
UroGen Pharma
Oct 16, 2024
Reiterates: Outperform
Price Target: $40
Current: $10.64
Upside: +275.94%
Immunovant
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $25.86
Upside: +104.95%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $26.49
Upside: -
Sep 25, 2024
Maintains: Outperform
Price Target: $15 → $43
Current: $13.07
Upside: +229.00%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $5.83
Upside: +414.58%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.65
Upside: +158.06%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $1.21
Upside: +1,966.12%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $19.03
Upside: +47.14%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $5.39
Upside: +363.82%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $53.60
Upside: +36.19%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $2.76
Upside: +624.64%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $21.27
Upside: +36.34%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $8.91
Upside: +292.82%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $1.01
Upside: +890.10%
Mar 28, 2024
Initiates: Outperform
Price Target: $5
Current: $3.49
Upside: +43.27%
Mar 21, 2024
Maintains: Outperform
Price Target: $9
Current: $4.05
Upside: +122.22%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.65
Upside: +1,112.12%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $245.44
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.80
Upside: +622.22%
Mar 24, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $0.61
Upside: +554.34%
Feb 22, 2023
Downgrades: Perform
Price Target: n/a
Current: $65.66
Upside: -
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.40
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $7,200
Current: $0.32
Upside: +2,248,494.63%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $22.09
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $2.65
Upside: +1,786.79%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $0.46
Upside: -